Sources: IUBMB Enzyme Nomenclature, NCBI Bookshelf, peer-reviewed enzymology and pharmacology literature. No sponsored claims. Uncertainty is labeled throughout.
Key Takeaways
- All proteases are peptidases (EC 3.4), but not every peptidase is acting as a broad protein-degrader: exopeptidases trim chain ends one residue at a time, while endopeptidases fragment internal bonds.
- DPP-4, a serine exopeptidase, inactivates GLP-1 within roughly 2 minutes in vivo; its inhibition by gliptins is one of the best-validated peptide-enzyme drug interactions in medicine.
- Digestive enzyme supplements list activity in HUT or PC units, not milligrams; a product with a higher mg dose can have lower actual proteolytic activity than a well-formulated lower-dose product.
- Most oral protease supplements lose a meaningful fraction of activity at gastric pH below 3 unless enteric-coated, a fact most product pages omit entirely.
- SARS-CoV-2 main protease (3CLpro) and the DPP-4 target in diabetes both confirm that specific protease inhibition is a mature, high-value drug strategy, not a fringe concept.
Peptidase vs Protease: The 50-Word Direct Answer
Peptidase and protease are formally synonymous: both name enzyme class EC 3.4, which hydrolyzes peptide bonds. In practice, protease usually refers to endopeptidases that fragment whole proteins, while peptidase often means exopeptidases that trim chain ends. Context, not a firm biological rule, determines which meaning is in use.
Table of Contents
- How are peptidases and proteases officially classified?
- How does each enzyme type actually cut a peptide bond?
- Evidence ledger: what we know and how confidently
- Why do digestive supplements list both protease and peptidase?
- What most pages get wrong about peptidases and proteases
- Why the rules of thumb exist: the chemistry behind pH stability
- Head-to-head: protease supplement vs digestive enzyme prescription
- Where protease and peptidase matter most clinically
- Operational label literacy: reading a protease supplement COA
- FAQ
- Sources
How Are Peptidases and Proteases Officially Classified?
The International Union of Biochemistry and Molecular Biology (IUBMB) places all peptide-bond-hydrolyzing enzymes under EC 3.4. The official IUBMB enzyme nomenclature uses "peptidases" as the class name for this entire group. "Protease" and "proteinase" are accepted synonyms used throughout the scientific literature without distinction.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Within EC 3.4, the critical split is structural, not terminological:
| Subclass | EC Sub-number | What it cuts | Examples |
|---|---|---|---|
| Aminopeptidases (exo) | EC 3.4.11 | N-terminal residues, one at a time | Leucine aminopeptidase, DPP-4 (cleaves two residues) |
| Dipeptidases (exo) | EC 3.4.13 | Dipeptides only | Cytosol nonspecific dipeptidase |
| Carboxypeptidases (exo) | EC 3.4.16-18 | C-terminal residues | Carboxypeptidase A, ACE (carboxypeptidase type) |
| Endopeptidases | EC 3.4.21-25, 99 | Internal peptide bonds | Trypsin (EC 3.4.21.4), pepsin (EC 3.4.23.1), papain (EC 3.4.22.2) |
The word "peptidase" in supplement labeling almost always means an exopeptidase that completes digestion at the brush border. The word "protease" in the same label almost always means an endopeptidase that initiates fragmentation of intact protein. Both are correct uses, just different layers of the same digestive cascade.
How Does Each Enzyme Type Actually Cut a Peptide Bond?
All proteases and peptidases hydrolyze the amide bond (CO-NH) between two amino acid residues using one of five catalytic mechanisms. The mechanism determines pH optimum, inhibitor sensitivity, and clinical drug-ability.
Serine proteases (EC 3.4.21): A catalytic triad of serine, histidine, and aspartate activates the serine hydroxyl to attack the carbonyl carbon. The serine acts as a nucleophile, forming a transient acyl-enzyme intermediate, which is then hydrolyzed by water. Trypsin, chymotrypsin, elastase, and thrombin are all serine proteases. DPP-4 (dipeptidyl peptidase-4) is a serine exopeptidase; its active site cleaves after a proline or alanine at position 2 from the N-terminus, which is why GLP-1 (which has an alanine at position 2) is a substrate.
Cysteine proteases (EC 3.4.22): A cysteine-histidine dyad is the catalytic unit. The thiol group of cysteine performs nucleophilic attack. Papain, caspases, and the SARS-CoV-2 3CLpro all use this mechanism. Cysteine proteases are generally sensitive to oxidizing conditions, which explains why plant-derived cysteine proteases like papain degrade in oxidizing formulations.
Aspartic proteases (EC 3.4.23): Two aspartate residues activate a catalytic water molecule. Pepsin (gastric, pH optimum roughly 1.5 to 2.5) and HIV protease are aspartic proteases. This class is unusual in requiring an acidic environment for peak activity.
Metalloproteinases (EC 3.4.24): A zinc or other metal ion activates water for nucleophilic attack. Angiotensin-converting enzyme (ACE) is a zinc metallocarboxypeptidase. Matrix metalloproteinases (MMPs) that remodel collagen are also in this class.
Threonine proteases (EC 3.4.25): The proteasome's catalytic subunits use an N-terminal threonine as the nucleophile. This class was recognized later and has become a drug target (bortezomib inhibits the 26S proteasome's threonine protease subunits in multiple myeloma treatment).
Evidence Ledger: What We Know and How Confidently
| Claim | Best Evidence Type | Effect Direction | Confidence |
|---|---|---|---|
| Peptidase and protease are EC 3.4 synonyms per IUBMB | Official nomenclature (IUBMB) | Established taxonomy | High |
| DPP-4 inhibitors extend GLP-1 half-life and improve glycemic control in T2D | Multiple large human RCTs (e.g., SAVOR-TIMI, TECOS) | Positive, clinically meaningful | High |
| Trypsin and chymotrypsin are the primary endopeptidases in human pancreatic juice | Biochemistry textbooks, human physiology studies | Established mechanism | High |
| Oral protease supplements improve symptoms in exocrine pancreatic insufficiency (EPI) | Human RCTs (pancreatic enzyme replacement therapy literature) | Positive | High (for diagnosed EPI) |
| Oral bromelain or papain supplements meaningfully improve digestion in healthy adults | Small RCTs, inconsistent endpoints | Mixed, modest at best | Low to Moderate |
| Nirmatrelvir (3CLpro inhibitor) reduces severe COVID-19 risk | EPIC-HR Phase 2/3 RCT (Hammond et al., NEJM 2022) | Positive (high-risk unvaccinated patients) | High (original population); Moderate (broader use) |
| Enteric coating preserves oral protease activity through gastric transit | In vitro dissolution studies, pharmacokinetic inference | Positive effect on delivered activity | Moderate |
| Oral protease supplements degrade co-administered oral peptide drugs | Mechanistic inference, no direct clinical RCT | Theoretically positive risk | Very Low (no direct human data) |
Why Do Digestive Supplements List Both Protease and Peptidase?
Protein digestion is a two-stage relay. Stage one happens in the gastric lumen and upper small intestine: endopeptidases (the "proteases" on a label) fragment intact dietary proteins into oligopeptides of varying lengths. Pepsin begins this in the stomach; pancreatic trypsin and chymotrypsin continue it in the duodenum. Trypsin preferentially cleaves after lysine and arginine residues; chymotrypsin prefers phenylalanine, tyrosine, and tryptophan. This specificity means no single endopeptidase can fully digest all dietary proteins.
Stage two occurs at the brush border and in the cytoplasm of enterocytes: exopeptidases (the "peptidases" on a label) clip the resulting oligopeptides down to di- and tripeptides or free amino acids. Di- and tripeptides are absorbed intact via the PepT1 transporter and then hydrolyzed intracellularly. Free amino acids are absorbed via amino acid transporters.
A supplement that provides only endopeptidase activity leaves a residue of oligopeptides that cannot be fully absorbed. A supplement that provides only exopeptidase activity has nothing to work on if the endopeptidases upstream are insufficient. This is why complete digestive enzyme products for conditions like EPI contain both classes, and why the labeling distinction is clinically meaningful even though the naming overlap is confusing.
What Most Pages Get Wrong About Peptidases and Proteases
The pH survival problem. Most supplement pages do not mention that the stomach regularly reaches pH 1.5 to 2 during active digestion. Bromelain has a reported activity range of roughly pH 4 to 8 in vitro and loses substantial activity below pH 3. Papain tolerates somewhat lower pH but is not gastric-acid-proof. Without enteric coating or buffering strategies, a meaningful fraction of supplemental protease activity is destroyed before it can reach the small intestine. Pancreatic enzyme replacement therapy (PERT) products for diagnosed EPI are enteric-coated for this reason.
The "systemic absorption" myth. Several consumer pages claim that oral proteases enter the bloodstream and have systemic anti-inflammatory effects by breaking down circulating proteins. Intact enzyme proteins are themselves peptides subject to digestion; the evidence that appreciable quantities of active protease enzyme cross the intestinal barrier in humans is weak. Any observed systemic effects of oral proteases most likely reflect downstream immune modulation from altered luminal peptide fragments, not circulating active enzyme. This distinction matters because it changes the mechanism entirely.
Confusing DPP-4 supplements with DPP-4 inhibitor drugs. Some wellness content claims that dietary "DPP-4 inhibitors" from food or supplements replicate gliptin drugs. DPP-4 is a membrane-bound serine peptidase. Pharmaceutical DPP-4 inhibitors achieve validated plasma concentrations sufficient to substantially reduce DPP-4 activity in vivo. Food compounds with in vitro DPP-4 inhibitory activity (certain dairy peptides, polyphenols) do not reach equivalent concentrations at the enzyme's active site in humans. The mechanism exists; the magnitude does not translate from in vitro to clinical practice at dietary doses.
Why the Rules of Thumb Exist: The Chemistry Behind pH Stability
The rule "store enzymes cold and away from acid" has a specific chemical basis. Enzymes are proteins whose tertiary structure depends on a network of hydrogen bonds, hydrophobic interactions, and (in some cases) disulfide bridges. Heat increases molecular kinetic energy, disrupting these non-covalent interactions and causing irreversible unfolding (denaturation). Once the active-site geometry is lost, the enzyme cannot form the transition-state complex with its substrate regardless of how much protein mass remains.
Acid does two things: it protonates catalytic residues (the histidine in a serine protease's triad must be in the correct protonation state for catalysis), and at extreme pH it can break hydrogen bonds that hold the protein fold together. This is why pepsin, an aspartic protease optimized for gastric acid, functions at pH 1.5 to 2 while trypsin, a serine protease optimized for the duodenum, has an activity optimum near pH 8.
For cysteine proteases like papain and bromelain, there is an additional concern: oxidation of the catalytic cysteine thiol. Exposure to atmospheric oxygen, metal ions, or oxidizing co-ingredients (vitamin C at high concentrations acts as a pro-oxidant in some formulations, not just an antioxidant) can convert the thiol to a sulfenic, sulfinic, or sulfonic acid derivative, all of which are catalytically inactive. This is the specific chemistry behind the formulation rule of not combining cysteine proteases with high-dose ascorbic acid in an unprotected aqueous medium.
Head-to-Head: OTC Protease Supplement vs Prescription PERT vs No Intervention
| Factor | OTC protease/digestive enzyme supplement | Prescription PERT (e.g., pancrelipase) | No enzyme supplementation |
|---|---|---|---|
| Regulatory status | Dietary supplement (not FDA-approved for disease) | FDA-approved NDA drug | N/A |
| Standardization | Variable; FCC units used but not uniformly enforced | USP units, lot-tested, NDA manufacturing standards | N/A |
| Evidence base for EPI | Not studied for diagnosed EPI; not indicated | Multiple RCTs; guideline-recommended | Malabsorption, steatorrhea, weight loss |
| Evidence base for healthy adults | Small RCTs, modest benefit signals | Not indicated; regulatory overstep | Adequate if own pancreatic function is normal |
| Enteric coating | Most products lack it; a minority are coated | Required; microsphere formulations standard | N/A |
| Cost per month | Low (roughly $15 to $50 USD) | High (often $200 to $600+ without insurance) | Zero |
| Where OTC loses | Activity standardization, gastric survival, no clinical indication data | Wins on all clinical and quality metrics for EPI | Wins on cost for healthy individuals with no deficiency |
The honest conclusion: for diagnosed exocrine pancreatic insufficiency, prescription PERT is not comparable to OTC products. For healthy adults with functional pancreata, evidence that OTC proteases provide meaningful benefit is thin. Neither category is well served by content that treats them interchangeably.
Where Protease and Peptidase Biology Matters Most Clinically
Type 2 diabetes (DPP-4). GLP-1 has a plasma half-life of roughly 1 to 2 minutes in vivo because DPP-4, circulating in plasma and expressed on endothelial and immune cells, rapidly cleaves the His-Ala N-terminus. Sitagliptin, saxagliptin, and other gliptins competitively inhibit DPP-4's serine active site, extending GLP-1 half-life several-fold. This is the most clinically validated example of exopeptidase pharmacology in metabolic medicine.
Antiviral therapy (3CLpro). SARS-CoV-2 encodes a polyprotein that must be cleaved by its own 3C-like cysteine protease (3CLpro, Mpro) to produce functional replication machinery. Nirmatrelvir forms a reversible covalent bond with the catalytic cysteine of 3CLpro, halting viral replication. The EPIC-HR trial (Hammond et al., NEJM 2022) showed significant reduction in hospitalization and death in high-risk unvaccinated adults. This is a clean example of viral protease inhibition as antiviral strategy.
Oncology (proteasome). The 26S proteasome's threonine protease activity degrades ubiquitinated proteins, including tumor-suppressor regulators. Bortezomib's proteasome inhibition is a validated mechanism in multiple myeloma.
Peptide drug bioavailability. The reason most research peptides (BPC-157, TB-500, CJC-1295) require subcutaneous injection is that luminal endopeptidases would degrade them before meaningful absorption. Semaglutide's oral formulation (Rybelsus) uses SNAC to promote absorption across the gastric mucosa, partly by creating a local microenvironment that limits protease exposure, not by defeating systemic proteolysis.
Operational Label Literacy: Reading a Protease Supplement or COA
Activity units matter more than weight. Look for HUT (Hemoglobin Units of Tyrosine), PC (Protease Units), or SAP (Spectrophotometric Acid Protease) units per the Food Chemical Codex (FCC). A label listing only milligrams of "protease blend" without activity units cannot be evaluated for potency.
Typical ranges. A functional digestive enzyme product commonly lists protease activity in the range of 20,000 to 100,000 HUT per serving. Products outside this range are not automatically better or worse; the appropriate amount depends on meal protein load and the individual's own protease output.
Enteric coating disclosure. The label or product description should state whether capsules are enteric-coated or whether enzyme particles are microencapsulated. If it does not state this, assume they are not. "Delayed release" capsules may offer some protection but are not equivalent to pharmaceutical microsphere technology.
COA red flags. A Certificate of Analysis from a reputable third-party lab should report activity units, not just identity by HPLC. Identity testing confirms the protein is present; activity testing confirms the protein is functional. A COA that shows only purity by weight without activity assay does not confirm potency.
Expiration and storage. Enzyme products should specify storage temperature (typically below 25 degrees C, away from humidity and light). A product stored in a warm shipping container or bathroom cabinet may have substantially reduced activity regardless of what the label states. Purchasing from retailers with climate-controlled storage and high turnover reduces this risk.
What a degraded product looks like. For powder or capsule proteases, there is no reliable visual indicator of activity loss. Color change or clumping may indicate moisture contamination but activity can decline before visible changes occur. For liquid formulations, cloudiness or precipitation can indicate protein aggregation and loss of native conformation.
FAQ
What is the difference between a peptidase and a protease?
Protease is the broad category: any enzyme that cleaves peptide bonds. Peptidase is a synonym for protease and is also used more narrowly to mean exopeptidases that trim single amino acids from chain ends, while endoproteases cut internal bonds. Context determines which meaning is intended.
Are peptidase and protease the same enzyme?
Formally yes. The IUBMB enzyme nomenclature class EC 3.4 is called both "peptidases" and "proteases" interchangeably. In everyday supplement and clinical language, protease often implies an endopeptidase that breaks down large proteins, while peptidase often refers to terminal-trimming exopeptidases.
What does an endopeptidase do versus an exopeptidase?
An endopeptidase cleaves peptide bonds within the interior of a polypeptide chain, producing smaller fragments. An exopeptidase removes one or two amino acids from either the N-terminus (aminopeptidase) or C-terminus (carboxypeptidase) of a chain, progressively shortening it.
Why do digestive enzyme supplements list both protease and peptidase?
The two enzyme types work sequentially. Proteases (endopeptidases like trypsin and chymotrypsin) break large dietary proteins into shorter peptides first. Peptidases (exopeptidases like brush-border aminopeptidases) then clip those peptides down to free amino acids that can be absorbed through the intestinal wall.
What are the five mechanistic classes of proteases?
IUBMB recognizes serine, cysteine, aspartic, metallo, and threonine proteases based on the catalytic residue or metal ion that activates the peptide bond for hydrolysis. Each class has distinct pH optima, inhibitor profiles, and physiological roles.
Do oral protease supplements survive stomach acid?
Most plant-derived proteases (bromelain, papain) retain partial activity across a wide pH range but still lose meaningful activity below pH 3. Enteric coating improves survival through gastric transit. Without it, a significant fraction of enzyme activity is destroyed before reaching the small intestine.
How do proteases affect therapeutic peptides like semaglutide or BPC-157?
Oral therapeutic peptides face rapid proteolytic degradation in the GI tract, which is the primary reason most peptide drugs require injection. Semaglutide oral tablets use a sodium N-acyl-8-aminocaprylic acid (SNAC) absorption enhancer partly to limit local protease exposure at the gastric mucosa.
What is dipeptidyl peptidase-4 (DPP-4) and why does it matter clinically?
DPP-4 is a serine exopeptidase that cleaves the two N-terminal amino acids from GLP-1 and GIP, inactivating them within minutes. DPP-4 inhibitors (gliptins) block this cleavage, extending incretin half-life. This is one of the best-validated peptidase drug targets in type 2 diabetes treatment.
What is protease specificity and why does it matter for supplements?
Protease specificity refers to the amino acid sequence or residue the enzyme preferentially cleaves adjacent to. Trypsin cuts after lysine and arginine. Chymotrypsin cuts after large hydrophobic residues. Specificity determines which proteins are digested efficiently and influences which peptide fragments are released.
Can taking a protease supplement degrade peptide research compounds?
Oral protease supplements theoretically increase luminal proteolytic activity, but the practical impact on co-administered injectable peptides (which bypass the GI tract) is negligible. For any orally administered peptide, concurrent protease supplement use could accelerate degradation, though direct clinical data on this interaction is lacking.
How do you read a digestive enzyme supplement label for protease activity?
Protease activity is measured in HUT (Hemoglobin Units of Tyrosine) or PC (Protease Units) per the Food Chemical Codex. A typical digestive enzyme product lists 20,000 to 100,000 HUT per serving. Comparing products requires using the same unit system; mg weight of enzyme protein is not equivalent to activity units.
Is there a protease involved in COVID-19 or antiviral drug targets?
Yes. SARS-CoV-2 encodes two cysteine proteases: 3CLpro (main protease, Mpro) and PLpro. Nirmatrelvir, the active ingredient in Paxlovid, is a reversible covalent inhibitor of 3CLpro. This is a high-profile example of a viral protease as a validated drug target.
Sources
- IUBMB Enzyme Nomenclature. EC 3.4: Acting on peptide bonds (peptidases). Available at: https://www.enzyme-database.org/
- Rawlings ND, Barrett AJ, Thomas PD, et al. The MEROPS database of proteolytic enzymes, their substrates and inhibitors. Nucleic Acids Research. 2018;46(D1):D624-D632.
- Chymotrypsin, trypsin, and pancreatic enzymes: Barrett AJ, Rawlings ND, Woessner JF, eds. Handbook of Proteolytic Enzymes. 2nd ed. Academic Press; 2004.
- Drucker DJ. The biology of incretin hormones. Cell Metabolism. 2006;3(3):153-165.
- Scirica BM, Bhatt DL, Braunwald E, et al. (SAVOR-TIMI 53). Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes. NEJM. 2013;369(14):1317-1326.
- Green JB, Bethel MA, Armstrong PW, et al. (TECOS). Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. NEJM. 2015;373(3):232-242.
- Hammond J, Leister-Tebbe H, Gardner A, et al. (EPIC-HR). Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. NEJM. 2022;386(15):1397-1408.
- Rehfeld JF. A centenary of gastrointestinal endocrinology. Hormone and Metabolic Research. 2004;36(11-12):735-741. (context for brush-border peptidase physiology)
- Halberg IB, Lyby K, Wassermann K, et al. Efficacy and safety of oral basal insulin versus subcutaneous insulin glargine in type 2 diabetes: a randomised, double-blind, phase 2 trial. Lancet Diabetes Endocrinology. 2019;7(3):179-188. (oral peptide bioavailability context)
- Food Chemical Codex (FCC). 12th edition. US Pharmacopeial Convention. Methods for enzyme activity including HUT and PC units.
- Whitcomb DC, Lowe ME. Human pancreatic digestive enzymes. Digestive Diseases and Sciences. 2007;52(1):1-17.
- Davidi D, Longo LM, Jabber-Ansari J, et al. A bird's-eye view of enzyme evolution: chemical, physicochemical, and physiological considerations. Chemical Reviews. 2018;118(18):8786-8797. (pH and catalytic mechanism basis)
Footer Disclaimers
Platform: This page is published by FormBlends for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before making any decisions about enzyme supplementation or peptide therapy.
Research Compound Notice: References to peptides such as BPC-157, TB-500, and CJC-1295 in the context of proteolytic degradation are made for educational illustration only. These compounds are not FDA-approved drugs and are not sold by FormBlends for human use.
Results: Individual responses to enzyme supplementation vary. The evidence described reflects population-level study data; no specific outcome is guaranteed for any individual.
Trademark: All drug and product names mentioned (Paxlovid, Rybelsus, Rybelsus, Januvia, etc.) are trademarks of their respective owners. FormBlends has no affiliation with those manufacturers.